DSpace@İnönü

Yazar "Paksoy, N" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Yazar "Paksoy, N" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Sırala: Sıra: Sonuçlar:

  • Real-world data on efficacy and safety of first-line alectinib treatment 
    Hizal, M; Bilgin, B; Paksoy, N; Kilickap, S; Atci, MM; Kahraman, S; Keskinkilic, M; Bilgetekin, I; Ayhan, M; Tural, D; Eren, O; Mustafayev, FNA; Yaman, S; Tatli, AM; Bayram, E; Kutlu, Y; Erturk, I; Ozcan, E; Gulmez, A; Korkmaz, M; Akagunduz, B; Erdem, D; Telli, TA; Aksoy, A; Uskent, N; Iriagac, Y; Baytemur, NK; Aydin, D; Sakalar, T; Arak, H; Selcukbiricik, F; Ergun, Y; Korkmaz, T; Ak, N; Unal, C; Akdeniz, N; Ozgun, MA; Oksuzoglu, B; Yalcin, B; Oztop, I; Algin, E; Sakin, A; Aydiner, A; Yumuk, PF; Sendur, MAN (2022)
    Plain language summary The advancements in cancer treatment, particularly in the last two decades, have been promising. Non-small-cell lung cancer (NSCLC) is one of the most important diseases experiencing these promising ...
  • The real-life efficacy and safety of osimertinib in pretreated advanced 
    Hizal, M; Bilgin, B; Paksoy, N; Acikgoz, O; Sezer, A; Gurbuz, M; Ak, N; Yucel, S; Ayhan, M; Erol, C; Demirkiran, A; Mandel, NM; Shbair, A; Gokmen, I; Basoglu, T; Paydas, S; Demiray, AG; Iriagac, Y; Sakalar, T; Zeynelgil, E; Tatli, AM; Bahceci, A; Guven, DC; Caner, B; Can, A; Gulmez, A; Karakas, Y; Yalcin, B; Demirkazik, A; Bilici, A; Aydiner, A; Yumuk, PF; Sendur, MAN (2022)
    Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ...